ATAI - ATAI Life Sciences BV

Momentum: Bearish

Recent News

Are Medical Stocks Lagging Halozyme Therapeutics ( HALO ) This Year?

Zacks Commentary • 1 week, 5 days ago • score: 0.11

Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Bullish

Here's Why atai Life Sciences ( ATAI ) Is a Great 'Buy the Bottom' Stock Now

Zacks Commentary • 4 weeks ago • score: 0.25

atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential ...

Bullish

Is atai Life Sciences ( ATAI ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 2 months ago • score: 0.50

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Bullish

Are Medical Stocks Lagging atai Life Sciences ( ATAI ) This Year?

Zacks Commentary • 2 months, 3 weeks ago • score: 0.43

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Bullish

Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. ( ATAI ) is a Great Choice

Zacks Commentary • 3 months ago • score: 0.31

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

ATA Creativity Global provides educational services to students in China. The company is headquartered in Beijing, China.

52W High

$5.34

52W Low

$1.03

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.56

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.27

EV/Revenue (<3 favorable)

386.66

P/S (TTM) (<3 favorable)

424.22

P/B (<3 favorable)

6.81

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

7.70%

Institutions (25–75% balanced)

39.81%

Shares Outstanding

214,338,000

Float

116,369,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

2,309,000

Gross Profit (TTM)

2,309,000

EPS (TTM)

-0.69

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-35.15%

ROE (TTM) (>15% strong)

-0.77%

EPS YoY (Quarterly) (>10% good)

-0.97

Revenue YoY (Quarterly) (>8% good)

1.63

Momentum

Bearish momentum

Value

0.2676

0.2903

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025